Lipid Profiles, Inflammatory Markers, and Insulin Therapy in Youth with Type 2 Diabetes
暂无分享,去创建一个
Ruth S. Weinstock | J. Bulger | S. Bristol | S. Narasimhan | N. Amodei | D. Gallagher | B. Anderson | J. Lima | W. Tamborlane | S. Caprio | M. Sadler | N. White | R. Danis | J. Shepherd | S. Gidding | K. Nadeau | D. Nathan | F. Kaufman | L. Pyle | E. Mayer-Davis | D. Wilfley | L. Delahanty | D. Hale | R. Berkowitz | T. Songer | M. Grey | T. Lipman | B. Linder | M. Haymond | L. Fisher | Y. Xu | L. Laffel | M. Geffner | L. Levitsky | K. Copeland | L. Cuttler | S. Thamotharan | R. Weinstock | J. Silverstein | R. Goland | C. Massmann | S. Arslanian | S. Chernausek | M. Palmert | R. Ratner | R. Izquierdo | P. Trief | G. Klingensmith | W. Dahms | M. Larkin | D. Norman | S. Neill | I. Libman | L. Higgins | A. Domalpally | E. Fleury-Milfort | N. Sherry | S. Estrada | A. Ward | S. Marcovina | S. Carnes | M. Kelsey | P. Zeitler | L. Pratt | D. M. Nathan | Fida Bacha | S. Edelstein | C. Ievers‐Landis | S. Narasimhan | Lorraine E. Levitt Katz | Samuel S. Gidding | Laure El ghormli | Ingrid Libman | Kristen J. Nadeau | Kristin Porter | Santica Marcovina | S. McKay | M. Haymond | B. Anderson | C. Bush | S. Gunn | H. Holden | S. M. Jones | G. Jeha | S. McGirk | S. Thamotharan | L. Cuttler | E. Abrams | T. Casey | W. Dahms | C. Ievers‐Landis | B. Kaminski | M. Koontz | S. MacLeish | P. McGuigan | M. Geffner | V. Barraza | N. Chang | B. Conrad | D. Dreimane | S. Estrada | L. Fisher | E. Fleury‐Milfort | S. Hernandez | B. Hollen | F. Kaufman | E. Law | V. Mansilla | D. Miller | C. Muñoz | R. Ortiz | A. Ward | K. Wexler | Y. K. Xu | P. Yasuda | R. Berkowitz | S. Boyd | B. Johnson | J. Kaplan | C. Keating | C. Lassiter | T. Lipman | G. McGinley | H. McKnight | B. Schwartzman | S. Willi | S. Arslanian | S. Foster | B. Galvin | T. Hannon | A. Kriska | M. Marcus | T. Songer | E. Venditti | R. Goland | D. Gallagher | P. Kringas | N. Leibel | D. Ng | M. Ovalles | D. Seidman | L. Laffel | A. Goebel‐Fabbri | M. Hall | L. Higgins | J. Keady | M. Malloy | K. Milaszewski | L. Rasbach | A. Angelescu | L. Bissett | C. Ciccarelli | L. Delahanty | V. Goldman | O. Hardy | M. Larkin | L. Levitsky | R. McEachern | D. Norman | D. Nwosu | S. Park‐Bennett | D. Richards | N. Sherry | B. Steiner | S. Tollefsen | S. Carnes | D. Dempsher | D. Flomo | T. Whelan | B. Wolff | D. Bowerman | J. Hartsig | R. Izquierdo | J. Kearns | R. Saletsky | P. Trief | P. Zeitler | N. Abramson | A. Bradhurst | N. Celona‐Jacobs | J. Higgins | M. Kelsey | G. Klingensmith | T. Witten | K. Copeland | E. Boss | R. Brown | J. Chadwick | L. Chalmers | S. Chernausek | A. Hebensperger | C. Macha | R. Newgent | A. Nordyke | D. Olson | T. Poulsen | L. Pratt | J. Preske | J. Schanuel | S. Sternlof | J. Lynch | N. Amodei | R. Barajas | C. Cody | D. Hale | J. Hernandez | C. Ibarra | E. Morales | S. Rivera | G. Rupert | A. Wauters | N. White | A. Arbeláez | J. Jones | T. Jones | M. Sadler | M. Tanner | A. Timpson | R. Welch | S. Caprio | M. Grey | C. Guandalini | S. Lavietes | P. Rose | A. Syme | W. Tamborlane | K. Hirst | S. Edelstein | P. Feit | N. Grover | C. Long | L. Pyle | B. Linder | J. Harting | J. Shepherd | B. Fan | L. Marquez | M. Sherman | J. Wang | M. Nichols | E. Mayer‐Davis | Y. Liu | J. Lima | J. Puccella | E. Ricketts | R. Danis | A. Domalpally | A. Goulding | S. Neill | P. Vargo | D. Wilfley | D. Aldrich‐Rasche | K. Franklin | C. Massmann | D. O'Brien | J. Patterson | T. Tibbs | D. Van Buren | M. Palmert | R. Ratner | D. Dremaine | J. Silverstein | F. Bacha | L. El ghormli | M. Tanner | D. Richards | D. Dempsher | Y. Liu | T. Tibbs | J. Kaplan | L. Levitt Katz | S. Lavietes | R. Saletsky | D. Seidman | P. Yasuda | J. Lynch | S. Tollefsen | S. McKay | T. Hannon | T. Jones | S. Willi | E. Ricketts | C. Muñoz | S. Gunn | O. Hardy | R. Newgent | S. Bristol | R. Welch | P. Feit | K. Hirst | A. Arbeláez | A. Goebel-Fabbri | D. Dreimane | C. Ibarra | M. Sherman | T. Witten | V. Goldman | J. Kearns | D. Bowerman | L. Chalmers | J. Chadwick | H. McKnight | C. Bush | S. Macleish | K. Milaszewski | C. Guandalini | P. Rose | C. Keating | J. Wang | G. Jeha | T. Whelan | M. Koontz | R. Ortíz | B. Kaminski | B. Conrad | J. Hernandez | P. McGuigan | N. Grover | N. Chang | B. Schwartzman | R. Barajas | N. Celona-Jacobs | D. V. Van Buren | N. Abramson | G. Rupert | A. Kriska | T. Casey | A. Wauters | B. Galvin | C. Lassiter | A. Syme | A. Timpson | J. Patterson | H. Holden | S. Jones | S. McGirk | E. Abrams | V. Barraza | B. Hollen | E. Law | V. Mansilla | K. Wexler | S. Boyd | B. Johnson | G. McGinley | S. Foster | M. Marcus | K. Porter | E. Venditti | P. Kringas | N. Leibel | D. Ng | M. Ovalles | M. Hall | J. Keady | M. Malloy | L. Rasbach | A. Angelescu | L. Bissett | C. Ciccarelli | R. McEachern | D. Nwosu | S. Park‐Bennett | B. Steiner | D. Flomo | B. Wolff | J. Bulger | J. Hartsig | A. Bradhurst | J. Higgins | E. Bošs | R. Brown | A. Hebensperger | C. Macha | A. Nordyke | D. Olson | T. Poulsen | J. Preske | J. Schanuel | S. Sternlof | C. Cody | E. Morales | S. Rivera | J. Jones | C. Long | J. Harting | B. Fan | L. Márquez | M. Nichols | J. Puccella | A. Goulding | P. Vargo | D. Aldrich‐Rasche | K. Franklin | D. O'Brien | D. Dremaine | S. Hernández | D. Miller | C. Ievers-Landis
[1] K. Flegal,et al. Characterizing extreme values of body mass index-for-age by using the 2000 Centers for Disease Control and Prevention growth charts. , 2009, The American journal of clinical nutrition.
[2] S. Caprio,et al. Lipid and Inflammatory Cardiovascular Risk Worsens Over 3 Years in Youth With Type 2 Diabetes , 2013, Diabetes Care.
[3] J. Viikari,et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Det , 2009, Journal of the American College of Cardiology.
[4] Amy S. Shah,et al. Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus: A Scientific Statement From the American Heart Association , 2014, Circulation.
[5] S. Kiechl,et al. Impaired glucose tolerance, Type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study , 2000, Diabetologia.
[6] B. U. Nwosu. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study , 2010 .
[7] Hyuni Lee,et al. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long‐term continuous subcutaneous insulin infusion , 2008, Diabetes/metabolism research and reviews.
[8] Amy S. Shah,et al. Influence of duration of diabetes, glycemic control, and traditional cardiovascular risk factors on early atherosclerotic vascular changes in adolescents and young adults with type 2 diabetes mellitus. , 2009, The Journal of clinical endocrinology and metabolism.
[9] M. Aslan,et al. Effect of insulin analog initiation therapy on LDL/HDL subfraction profile and HDL associated enzymes in type 2 diabetic patients , 2013, Lipids in Health and Disease.
[10] B. Anderson,et al. Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes , 2016, Diabetes Care.
[11] D. Nathan,et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. , 2012, The New England journal of medicine.
[12] D. Goff,et al. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). , 2014, The American journal of cardiology.
[13] P. Ridker. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. , 2003, Circulation.
[14] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[15] N M Laird,et al. Tutorial in Biostatistics: Evaluating the impact of 'critical periods' in longitudinal studies of growth using piecewise mixed effects models. , 2001, International journal of epidemiology.
[16] K. Okumura,et al. Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus. , 2007, Metabolism: clinical and experimental.
[17] W. Tamborlane,et al. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes , 2007, Pediatric diabetes.
[18] Diederick Grobbee,et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.
[19] K. Cusi,et al. Safety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM , 1995, Diabetes Care.
[20] Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. , 1995, The American journal of cardiology.
[21] S. Daniels,et al. Increased arterial stiffness is found in adolescents with obesity or obesity-related type 2 diabetes mellitus , 2010, Journal of hypertension.
[22] R. Wolfinger,et al. SAS for Mixed Models , 2018 .
[23] F. Nuttall,et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus. , 1998, Archives of internal medicine.
[24] Amy S. Shah,et al. Lipids and lipoprotein ratios: contribution to carotid intima media thickness in adolescents and young adults with type 2 diabetes mellitus. , 2013, Journal of clinical lipidology.
[25] H. Ginsberg,et al. Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance , 2011, Trends in Endocrinology & Metabolism.
[26] A. Chait,et al. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. , 2004, Diabetes.
[27] I. Buchan,et al. Why have sustained increases in obesity and type 2 diabetes not offset declines in cardiovascular mortality over recent decades in Western countries? , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[28] H. Yki-Järvinen,et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study , 2006, Diabetologia.
[29] Salim Yusuf,et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.
[30] Chin-Lee Wu,et al. Insulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway , 2009, PloS one.
[31] Grant D. Huang,et al. Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.
[32] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[33] C. Tack,et al. Start of insulin therapy in patients with type 2 diabetes mellitus promotes the influx of macrophages into subcutaneous adipose tissue , 2013, Diabetologia.
[34] B. U. Nwosu,et al. Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study , 2010, International Journal of Obesity.
[35] S. Gortmaker,et al. Health and economic burden of the projected obesity trends in the USA and the UK , 2011, The Lancet.
[36] G. Riccardi,et al. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients. , 2000, The Journal of clinical endocrinology and metabolism.